inclusion criteria: adult males age ≥18 years of age at the time of randomization are currently not hospitalized for acute respiratory symptoms (not applicable for subjects whose countries require mild to moderate covid-19 patients to be hospitalised, such as covid-19 patients in mainland china) the subject's first positive sars-cov-2 viral infection test result (using an approved molecular test, or other approved commercial or public health assay on any approved specimen) must be ≤3 days prior to randomization subjects with adequate liver and renal function agree to the collection of nasopharyngeal swabs and venous blood the participant or legally authorized representative signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: adult males age ≥18 years of age at the time of randomization are currently not hospitalized for acute respiratory symptoms (not applicable for subjects whose countries require mild to moderate covid-19 patients to be hospitalised, such as covid-19 patients in mainland china) the subject's first positive sars-cov-2 viral infection test result (using an approved molecular test, or other approved commercial or public health assay on any approved specimen) must be ≤3 days prior to randomization subjects with adequate liver and renal function agree to the collection of nasopharyngeal swabs and venous blood the participant or legally authorized representative signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: 1. adult males age ≥18 years of age at the time of randomization 2. are currently not hospitalized for acute respiratory symptoms (not applicable for subjects whose countries require mild to moderate covid-19 patients to be hospitalised, such as covid-19 patients in mainland china) 3. the subject's first positive sars-cov-2 viral infection test result (using an approved molecular test, or other approved commercial or public health assay on any approved specimen) must be ≤3 days prior to randomization 4. subjects with adequate liver and renal function 5. agree to the collection of nasopharyngeal swabs and venous blood 6. the participant or legally authorized representative signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: 1. adult males age ≥18 years of age at the time of randomization 2. are currently not hospitalized for acute respiratory symptoms (not applicable for subjects whose countries require mild to moderate covid-19 patients to be hospitalised, such as covid-19 patients in mainland china) 3. the subject's first positive sars-cov-2 viral infection test result (using an approved molecular test, or other approved commercial or public health assay on any approved specimen) must be ≤3 days prior to randomization 4. subjects with adequate liver and renal function 5. agree to the collection of nasopharyngeal swabs and venous blood 6. the participant or legally authorized representative signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol